Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PSEN1 | P49768 | 2/20 | 0.54 |
| ▸ | PSEN2 | P49810 | 2/20 | 0.54 |
| ▸ | APH1B | Q8WW43 | 2/20 | 0.54 |
| ▸ | NCSTN | Q92542 | 2/20 | 0.54 |
| ▸ | APH1A | Q96BI3 | 2/20 | 0.54 |
| ▸ | PSENEN | Q9NZ42 | 2/20 | 0.54 |
| ▸ | FFAR1 | O14842 | 12/20 | 0.40 |
| ▸ | PTPN2 | P17706 | 1/20 | 0.36 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.36 |
| ▸ | PTPN6 | P29350 | 1/20 | 0.36 |
| ▸ | PPARD | Q03181 | 3/20 | 0.36 |
| ▸ | PPARA | Q07869 | 3/20 | 0.36 |
| ▸ | PPARG | P37231 | 2/20 | 0.36 |
| ▸ | MAOB | P27338 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10077778 | 1.00 | PSEN1 (0.54) | PSEN1PSEN2APH1BNCSTNAPH1A | |
| SCHEMBL8054840 | 1.00 | PSEN1 (0.54) | PSEN1PSEN2APH1BNCSTNAPH1A | |
| SCHEMBL12781785 | 0.92 | PSEN1 (0.42) | PSEN1PSEN2APH1BNCSTNAPH1A | |
| SCHEMBL12781784 | 0.92 | PSEN1 (0.42) | PSEN1PSEN2APH1BNCSTNAPH1A | |
| SCHEMBL10085029 | 0.90 | PSEN1 (0.54) | PSEN1PSEN2APH1BNCSTNAPH1A | |
| SCHEMBL2068586 | 0.86 | PSEN1 (0.49) | PSEN1PSEN2APH1BNCSTNAPH1A | |
| SCHEMBL8075267 | 0.86 | PSEN1 (0.49) | PSEN1PSEN2APH1BNCSTNAPH1A | |
| SCHEMBL8068103 | 0.86 | PSEN1 (0.49) | PSEN1PSEN2APH1BNCSTNAPH1A | |
| SCHEMBL2904877 | 0.82 | CSNK2B (0.36) | PSEN1PSEN2APH1BNCSTNAPH1A | |
| SCHEMBL12781779 | 0.82 | PSEN1 (0.42) | PSEN1PSEN2APH1BNCSTNAPH1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2021314-B1 | SUBSTITUTED BIPHENYL CARBOXYLIC ACIDS AND DERIVATIVES THEREOF | ORTHO MCNEIL JANSSEN PHARM (US) | 2013-01-23 | — | — | EP | disclosed |
| EP-2215044-B1 | BIPHENYL CARBOXYLIC ACIDS AND DERIVATIVES THEREOF | JANSSEN PHARMACEUTICA NV (BE) | 2012-08-29 | — | — | EP | disclosed |
| US-8252935-B2 | Piperidinyl and piperazinyl modulators of γ-secretase | JANSSEN PHARMACEUTICA N.V. (BE) | 2012-08-28 | — | — | US | disclosed |
| EP-2016039-B1 | TERPHENYL DERIVATIVES FOR TREATMENT OF ALZHEIMER' S DISEASE | ORTHO MCNEIL JANSSEN PHARM (US) | 2012-08-01 | — | — | EP | disclosed |
| EP-2212287-B1 | PIPERIDINYL AND PIPERAZINYL MODULATORS OF y-SECRETASE | JANSSEN PHARMACEUTICA NV (BE) | 2012-02-01 | — | — | EP | disclosed |
| US-8106236-B2 | Triaryl compounds and derivates thereof | ORTHO-MCNEIL PHARMACEUTICAL, INC. (US) | 2012-01-31 | — | — | US | disclosed |
| US-7897643-B2 | Biphenyl carboxylic acids and derivatives thereof | JANSSEN PHARMACEUTICA N.V. (BE) | 2011-03-01 | — | — | US | disclosed |
| EP-2215044-A1 | BIPHENYL CARBOXYLIC ACIDS AND DERIVATIVES THEREOF | Janssen Pharmaceutica, N.V. (BE) | 2010-08-11 | — | — | EP | disclosed |
| EP-2212287-A1 | PIPERIDINYL AND PIPERAZINYL MODULATORS OF y-SECRETASE | Janssen Pharmaceutica, N.V. (BE) | 2010-08-04 | — | — | EP | disclosed |
| EP-2209764-A1 | GSM INTERMEDIATES | Janssen Pharmaceutica, N.V. (BE) | 2010-07-28 | — | — | EP | disclosed |
| US-20090105344-A1 | BIPHENYL CARBOXYLIC ACIDS AND DERIVATIVES THEREOF | JANSSEN PHARMACEUTICA N.V. (BE) | 2009-04-23 | — | — | US | disclosed |
| WO-2009052341-A1 | GSM INTERMEDIATES | JANSSEN PHARMACEUTICA, N.V. (BE) | 2009-04-23 | — | — | WO | disclosed |
| WO-2009052126-A1 | PIPERIDINYL AND PIPERAZINYL MODULATORS OF γ-SECRETASE | JANSSEN PHARMACEUTICA, N.V. (BE) | 2009-04-23 | — | — | WO | disclosed |
| US-20090105275-A1 | PIPERIDINYL AND PIPERAZINYL MODULATORS OF y-SECRETASE | JANSSEN PHARMACEUTICA N.V. (BE) | 2009-04-23 | — | — | US | disclosed |
| EP-2021314-A1 | SUBSTITUTED BIPHENYL CARBOXYLIC ACIDS AND DERIVATIVES THEREOF | Ortho-McNeil Pharmaceutical, Inc. (US) | 2009-02-11 | — | — | EP | disclosed |
| EP-2016039-A1 | TERPHENYL DERIVATIVES FOR TREATMENT OF ALZHEIMER' S DISEASE | Ortho-Mcneil Pharmaceutical, Inc. (US) | 2009-01-21 | — | — | EP | disclosed |
| US-20070293567-A1 | SUBSTITUTED BIPHENYL CARBOXYLIC ACIDS AND DERIVATIVES THEREOF | ORTHO-MCNEIL PHARMACEUTICAL, INC. | 2007-12-20 | — | — | US | disclosed |
| WO-2007124351-A1 | TERPHENYL DERIVATIVES FOR TREATMENT OF ALZHEIMER' S DISEASE | ORTHO-MCNEIL PHARMACEUTICAL, INC. (US) | 2007-11-01 | — | — | WO | disclosed |
| US-20070254957-A1 | TRIARYL COMPOUNDS AND DERIVATES THEREOF | ORTHO-MCNEIL PHARMACEUTICAL, INC. | 2007-11-01 | — | — | US | disclosed |
| WO-2007124394-A1 | SUBSTITUTED BIPHENYL CARBOXYLIC ACIDS AND DERIVATIVES THEREOF | ORTHO-MCNEIL PHARMACEUTICAL, INC. (US) | 2007-11-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090105275-A1 | PIPERIDINYL AND PIPERAZINYL MODULATORS OF y-SECRETASE | BACE1, BACE2, PSEN1 | PSEN1 3/4885PSEN2 5/4885APH1B 7/4885 |
| US-20070293567-A1 | SUBSTITUTED BIPHENYL CARBOXYLIC ACIDS AND DERIVATIVES THEREOF | BACE1, BACE2, APP | PSEN1 4/4885PSEN2 5/4885APH1B 6/4885 |
| US-20090105344-A1 | BIPHENYL CARBOXYLIC ACIDS AND DERIVATIVES THEREOF | BACE1, BACE2, APP | PSEN1 4/4885PSEN2 6/4885APH1B 7/4885 |
| US-20070254957-A1 | TRIARYL COMPOUNDS AND DERIVATES THEREOF | BACE1, BACE2, APP | PSEN1 4/4885PSEN2 5/4885APH1B 12/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.